Sample requirements

Arrow In this section
Investigation Blood sample requirement Result / report available

Myeloid Gene panel analysis

by Next Generation Sequencing

 

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

 

 

 

Up to 21 calendar days

 

 

Acute Myeloid Leukaemia (AML) – rapid analysis testing

 

FLT3 ITD/TKD

NPM1

 

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

 

Up to 5 calendar days for FLT3

Up to 14 calendar days for NPM1

 

NPM1 screening is usually performed in parallel with FLT3, therefore the TAT may be shorter.

Acute Myeloid Leukaemia (AML) –fusion detection and MRD monitoring

 

NPM1

CBFβ-MYH11 inv(16)

AML1-ETO t(8;21)

 

15-20 mL EDTA-anticoagulated peripheral blood and 2-3 mL EDTA-anticoagulated bone marrow

Up to 14 calendar days

 

For clinical urgency based upon priority clinical needs, a request can be made, and a 1 week turn around time arranged with the Lab.

APL – fusion detection and MRD monitoring

 

PML-RARA t(15;17)

 

 

15-20 mL EDTA-anticoagulated peripheral blood and 2-3 mL EDTA-anticoagulated bone marrow

 

Up to 14 calendar days

 

For clinical urgency based upon priority clinical needs, a request can be made, and a 1 week turn around time arranged with the Lab

CML and ALL – fusion detection and MRD monitoring

 

BCR-ABL t(9;22)

 

 

 

 

 

 

 

 

BCR-ABL kinase domain mutation analysis

 

 

 

15-20 mL EDTA-anticoagulated peripheral blood and / or 2-3 mL EDTA-anticoagulated bone marrow when required

 

 

 

 

 

Same as above.

Please note: A separate sample is not required if MRD monitoring and AKD analysis are requested together.

Up to 14 calendar for CML and ALL*

For clinical urgency based upon priority clinical needs, a request can be made, and a 1 week turn around time arranged with the Lab.

*Please note if BCR-ABL major negative, and where indicated, reflex testing for BCR-ABL minor will be performed.  This may increase the quoted TAT .

 

Up to 21 calendar days

For clinical urgency based upon priority clinical needs, a request can be made, and a shorter turn around time arranged with the Lab.

 

 

Myeloproliferative neoplasms

PV, ET and IMF

 

MPN panel (JAK2, CALR, MPL)

 

 

 

4 mL EDTA-anticoagulated peripheral blood

 

 

Up to 21 calendar days

 

For clinical urgency based upon priority clinical needs, a request can be made, and a shorter turn around time arranged with the Lab.

B and T Cell clonality analysis

 

Immunoglobulin and T cell receptor clonality analysis

 

Formalin fixed parafin embedded tissue (5×10µM scrolls).

For peripheral blood screen 4 mL EDTA PB or a bone marrow aspirate screen 2-3 mL EDTA BM

 

 

Up to 14 calendar days

Lymphoid Gene Panel Analysis

by Next Generation Sequencing,

including MYD88 for Waldenstrom’s Macroglobulinaemia (WM)

 

 

 

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

 

Formalin fixed parafin embedded tissue (5×10µM scrolls).

 

 

Up to 21 calendar days

 

Chronic Lymphocytic Leukaemia (CLL)

 

IGH Somatic Hypermutation analysis  (IGHV mutation analysis)

 

 

CLL gene panel analysis including TP53

 

 

 

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

 

 

Same as above.

Please note: A separate sample is not required if IGHV and gene panel analysis are requested together unless FFPE is sent for lymphoid panel testing.

 

 

 

Up to 21 calendar days

 

 

 

 

Up to 21 calendar days

 

Hairy Cell Leukaemia (HCL)

 

BRAF V600E mutation analysis

 

 

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

 

 

 

Up to 21 calendar days

Whole Genome sequencing (WGS)

 

 

 

 

 

 

 

https://mft.nhs.uk/nwglh/test-information/cancer/solid-tumour/whole-genome-sequencing-for-cancer/

4 – 6 weeks

Please note that for a few specialist tests, samples will be referred to one of the other GLH laboratories but sample referral and reporting will be handled by the NW-GLH via the HMDS service with the exception of ALL MRD samples (adult and paediatric) which should continue to be sent according to current pathways until further notice. 

Samples from AML patients whose MRD analysis was previously undertaken elsewhere should be sent to the same external centre for the duration of the patient’s management.

As the test directory will be regularly updated there may be some new or rare targets not currently available. If this is the case the laboratory will contact you to discuss testing options.